Neurocrine Announces INGREZZA(TM) Long-Term Safety and Efficacy Data to be Presented at the 2017 American Academy of Neurology Annual Meeting
Additional results from largest ever clinical program in tardive dyskinesia to be highlighted as platform and poster presentations
SAN DIEGO, April 21, 2017 -- (Healthcare Sales & Marketing Network) -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announ... Biopharmaceuticals, Neurology Neurocrine Biosciences, INGREZZA, valbenazine, tardive dyskinesia
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news